Business Standard | Dr Reddy's, Intas to tap India's Herceptin market Business Standard DRL, the first company to launch a monoclonal antibody biosimilar in India, had launched Reditux (Rituximab) used in the treatment of Non-Hodgkin's lymphoma (a kind of blood cancer) in 2007. On plans of launching Herceptin biosimilar, a DRL ... |
